Maintaining Patency in Implanted Port Catheters

September 15, 2022 updated by: Rachel Baker, TriHealth Inc.

Maintaining Patency in Implanted Port Catheters With Saline Only Flushes

The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in implanted port catheters. The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline.

Study Overview

Detailed Description

The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in implanted port catheters. The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline. These complications include partial or complete obstruction, infection of the central line, and/or the onset of heparin induced thrombocytopenia.

Study Type

Interventional

Enrollment (Actual)

436

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Cincinnati, Ohio, United States, 45220
        • TriHealth Cancer Institute Good Samaritan Infusion Center at GSH
      • Cincinnati, Ohio, United States, 45242
        • Ambulatory Treatment Center at Bethesda North TriHealth Hospital
      • Cincinnati, Ohio, United States, 45242
        • TriHealth Cancer Institute Good Samaritan Infusion Center, Medicenter
      • Cincinnati, Ohio, United States, 45247
        • TriHealth Cancer Institute Good Samaritan Infusion Center, Cheviot
      • Cincinnati, Ohio, United States, 45255
        • TriHealth Cancer Institute Good Samaritan Infusion Center, Anderson
      • Cincinnati, Ohio, United States, 45219
        • UC Health Barrett Infusion Center
      • Hamilton, Ohio, United States, 45011
        • TriHealth Cancer Institute Good Samaritan Infusion Center Butler County
      • Oxford, Ohio, United States, 45056
        • McCullough Hyde Memorial Hospital Infusion Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to read and understand English
  • Has an implanted port in place less than one (1) year
  • Evidence of a patent (unobstructed) port catheter prior to enrollment in the study
  • Is receiving active treatment (i.e., receiving a therapeutic drug through the implanted port)
  • Current treatment protocol projected to continue for a minimum of three (3) months
  • Anticipates receiving care at the identified centers for 12 months following enrollment in the study
  • Does not receive care of implanted port at any other facility

Exclusion Criteria:

  • Has documented heparin platelet antibody (i.e., could not be randomized to either group) or other allergy to heparin
  • Receiving therapeutic dose of an anticoagulant (e.g.,warfarin, heparin, enoxaparin)
  • Does not have a BioFlo port (heparinized port)
  • Does not meet one or more of the inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group
Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
Experimental: Intervention Group
Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
The intervention group will have their port catheters flushed with saline only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With First Complete Occlusion Within 1 Year
Time Frame: baseline to 1 year
Number of participants who had a first complete occlusion (Blockage) within 1 year
baseline to 1 year
Number of Participants With First Partial Occlusion Within 1 Year
Time Frame: baseline to 1 year
Number of Participants with First Partial Occlusion (Blockage) within 1 year
baseline to 1 year
Number of Participants With First Cathflo Administration for Occlusion (Blockage) Within 1 Year
Time Frame: baseline to 1 year
Number of Participants with First Cathflo administration for Occlusion (Blockage) within 1 year
baseline to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With First Complete or Partial Occlusion Within 1 Year
Time Frame: baseline to 1 year
Number of Participants with either a First Complete or Partial Occlusion (Blockage) within 1 year
baseline to 1 year
Number of Participants With HIT Within 1 Year
Time Frame: baseline to 1 year
Heparin Induced Thrombocytopenia (HIT) as measured by a positive HIT antibody test, or any other heparin allergy, will be recorded.
baseline to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Sarah Pelgen, BSN, RN, OCN, TriHealth Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2013

Primary Completion (Actual)

December 11, 2021

Study Completion (Actual)

December 17, 2021

Study Registration Dates

First Submitted

January 29, 2015

First Submitted That Met QC Criteria

January 29, 2015

First Posted (Estimate)

February 3, 2015

Study Record Updates

Last Update Posted (Actual)

October 12, 2022

Last Update Submitted That Met QC Criteria

September 15, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 12135-12-079

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe